Which has preferable valuation and earnings, ROIV or ARGX?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,966.77 -$299.77M -$0.60 N/A argenex $4.25B 12.99 $1.29B $22.46 39.50

Is ROIV or ARGX more profitable?

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -3,629.19%. argenex's return on equity of 44.37% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Roivant Sciences -3,629.19% -20.54% -19.43% argenex 31.31% 44.37% 37.55%

Does the media favor ROIV or ARGX?

In the previous week, argenex had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for argenex and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.12 beat argenex's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ROIV or TAK?

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 1.41%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer ROIV or TAK?

In the previous week, Roivant Sciences had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Roivant Sciences and 4 mentions for Takeda Pharmaceutical. Roivant Sciences' average media sentiment score of 1.12 beat Takeda Pharmaceutical's score of 0.12 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RVMD or ROIV?

In the previous week, Revolution Medicines and Revolution Medicines both had 8 articles in the media. Roivant Sciences' average media sentiment score of 1.12 beat Revolution Medicines' score of 0.34 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or ONC?

In the previous week, BeOne Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for BeOne Medicines and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.12 beat BeOne Medicines' score of 0.18 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Roivant Sciences (ROIV) Competitors

$34.07 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$34.06 -0.01 (-0.01%)

As of 06/26/2026 05:52 PM Eastern

Compare

ROIV vs. ARGX, TAK, TEVA, RVMD, and ONC

Should you buy Roivant Sciences stock or one of its competitors? MarketBeat compares Roivant Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roivant Sciences include argenex (ARGX), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Roivant Sciences compare to argenex?

Roivant Sciences (NASDAQ:ROIV) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
argenex	$4.25B	12.99	$1.29B	$22.46	39.50

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -3,629.19%. argenex's return on equity of 44.37% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
argenex	31.31%	44.37%	37.55%

In the previous week, argenex had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 12 mentions for argenex and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.12 beat argenex's score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Roivant Sciences presently has a consensus target price of $33.59, suggesting a potential downside of 1.41%. argenex has a consensus target price of $1,023.39, suggesting a potential upside of 15.35%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Takeda Pharmaceutical?

Roivant Sciences (NASDAQ:ROIV) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 1.41%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Takeda Pharmaceutical has a net margin of 4.31% compared to Roivant Sciences' net margin of -3,629.19%. Takeda Pharmaceutical's return on equity of 11.20% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

In the previous week, Roivant Sciences had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Roivant Sciences and 4 mentions for Takeda Pharmaceutical. Roivant Sciences' average media sentiment score of 1.12 beat Takeda Pharmaceutical's score of 0.12 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has higher earnings, but lower revenue than Takeda Pharmaceutical. Roivant Sciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81

Summary

Roivant Sciences beats Takeda Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Roivant Sciences (NASDAQ:ROIV) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential downside of 1.41%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 25.68%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Roivant Sciences' net margin of -3,629.19%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 8 mentions for Roivant Sciences. Teva Pharmaceutical Industries' average media sentiment score of 1.27 beat Roivant Sciences' score of 1.12 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	11 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99

Summary

Teva Pharmaceutical Industries beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Revolution Medicines currently has a consensus target price of $123.72, indicating a potential downside of 32.05%. Roivant Sciences has a consensus target price of $33.59, indicating a potential downside of 1.41%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has lower revenue, but higher earnings than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,342.85	-$1.13B	-$7.07	N/A
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A

Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Revolution Medicines and Revolution Medicines both had 8 articles in the media. Roivant Sciences' average media sentiment score of 1.12 beat Revolution Medicines' score of 0.34 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to BeOne Medicines?

Roivant Sciences (NASDAQ:ROIV) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential downside of 1.41%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 39.34%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Roivant Sciences' net margin of -3,629.19%. BeOne Medicines' return on equity of 12.06% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, BeOne Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for BeOne Medicines and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.12 beat BeOne Medicines' score of 0.18 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.51B	$3.63B	$7.03B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-56.78	21.56	26.13	24.16
Price / Sales	2,966.77	334.26	555.66	102.83
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.64	8.31	10.78	6.38
Net Income	-$299.77M	$23.92M	$3.58B	$337.00M
7 Day Performance	9.02%	1.93%	1.97%	-0.20%
1 Month Performance	13.60%	-0.41%	-0.24%	-1.40%
1 Year Performance	199.12%	65.22%	34.39%	27.76%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	2.0299 of 5 stars	$34.07 flat	$33.59 -1.4%	+199.1%	$24.51B	$8.26M	N/A	860	Positive News Insider Trade High Trading Volume
ARGX argenex	4.1931 of 5 stars	$903.75 +3.0%	$1,019.50 +12.8%	+58.4%	$54.58B	$4.25B	40.24	1,863	News Coverage Analyst Forecast
TAK Takeda Pharmaceutical	2.2728 of 5 stars	$15.46 -1.1%	N/A	+5.4%	$49.74B	$28.32B	39.63	47,455	News Coverage Analyst Downgrade
TEVA Teva Pharmaceutical Industries	4.8566 of 5 stars	$32.25 +2.4%	$41.78 +29.6%	+98.4%	$36.20B	$17.35B	24.24	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6462 of 5 stars	$165.81 +1.7%	$123.72 -25.4%	+393.3%	$34.65B	$11.58M	N/A	250	Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Takeda Pharmaceutical?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Roivant Sciences compare to argenex?

Which has preferable valuation and earnings, ROIV or ARGX?

Is ROIV or ARGX more profitable?

Does the media favor ROIV or ARGX?

Do institutionals & insiders hold more shares of ROIV or ARGX?

Which has more volatility and risk, ROIV or ARGX?

Do analysts rate ROIV or ARGX?

Summary

How does Roivant Sciences compare to Takeda Pharmaceutical?

Do analysts rate ROIV or TAK?

Do insiders and institutionals believe in ROIV or TAK?

Is ROIV or TAK more profitable?

Which has more volatility & risk, ROIV or TAK?

Does the media prefer ROIV or TAK?

Which has preferable earnings and valuation, ROIV or TAK?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Do analysts rate ROIV or TEVA?

Do institutionals & insiders hold more shares of ROIV or TEVA?

Is ROIV or TEVA more profitable?

Which has more risk and volatility, ROIV or TEVA?

Does the media prefer ROIV or TEVA?

Which has preferable valuation & earnings, ROIV or TEVA?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Do insiders & institutionals have more ownership in RVMD or ROIV?

Do analysts recommend RVMD or ROIV?

Which has preferable valuation & earnings, RVMD or ROIV?

Which has more risk & volatility, RVMD or ROIV?

Is RVMD or ROIV more profitable?

Does the media refer more to RVMD or ROIV?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Do analysts prefer ROIV or ONC?

Which has better earnings & valuation, ROIV or ONC?

Which has more risk & volatility, ROIV or ONC?

Do institutionals & insiders believe in ROIV or ONC?

Is ROIV or ONC more profitable?

Does the media prefer ROIV or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools